Millions of women with hypothyroidism and Hashimoto’s disease are at risk of losing access to the medication that keeps them healthy.

Natural desiccated thyroid (NDT) medications — such as Armour®, NP Thyroid®, and others — contain both T4 and T3 hormones, closely mimicking what the human thyroid naturally produces. For many women, synthetic T4-only or T3-only medications do not adequately manage symptoms like fatigue, brain fog, weight gain, and depression. Without NDT, countless patients could face a return of these debilitating symptoms.

The urgent problem:

On August 6, 2025, the FDA issued warning letters to manufacturers and distributors of NDT because these products are not currently FDA-approved. While safety and consistency in medications are essential, these actions could lead to restricted access or complete removal of NDT from the U.S. market — without a clear, immediate replacement for patients who depend on it.

This is not just a medication access issue — it’s a women’s health crisis.

• Hypothyroidism affects an estimated 14 million people in the U.S.
• 80–90% of those diagnosed are women.
• NDT has been prescribed safely for decades and remains the only option that provides both T4 and T3 in a natural balance for certain patients.

Losing NDT would disproportionately harm women’s health, livelihoods, and quality of life.

What we’re asking:

We call on the FDA and lawmakers to:

• Allow NDT to remain available while manufacturers work toward FDA approval.
• Provide an expedited pathway to meet FDA standards without disrupting care.
• Engage with patients and clinicians to ensure policy decisions reflect real-world treatment needs.

We believe in patient choice, individualized care, and the right to work with our healthcare providers to find the treatment that works best for us.

📢 Please sign and share this petition to protect access to safe, regulated, and effective NDT for the millions who rely on it to live full, healthy lives.